Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients

Alessandro Martorana, Zaira Esposito, Francesco Di Lorenzo, Viola Giacobbe, Giulia Maria Sancesario, Giulia Bucchi, Sonia Bonnì, Sergio Bernardini, Roberto Sorge, Giuseppe Sancesario, Giorgio Bernardi, Carlo Caltagirone, Giacomo Koch

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The dysfunction of cholinergic neurons is a typical hallmark in Alzheimer's disease (AD). In animal models of AD, fragments of amyloid beta protein (Aβ) and Tau protein are thought to interfere with central cholinergic transmission, specifically with synthesis and release of acetylcholine. Thus, we aimed to investigate whether the cerebrospinal fluid (CSF) levels of Aβ42 and Tau proteins in AD patients could influence physiological central cholinergic activity. In AD patients (n = 19), central cholinergic function was evaluated in vivo by using short afferent latency inhibition (SLAI), and compared to age-matched healthy controls. In the same AD patients, CSF samples were collected through lumbar puncture to obtain individual levels of Aβ42, total Tau (t-Tau) and phosphorylated Tau (p-Tau) (Thr181). SLAI was decreased in AD patients in comparison to age-matched healthy controls. We found that in patients there was a negative correlation between the individual amount of cholinergic activity assessed by SLAI and the CSF levels of Aβ42. On the other hand, there was a positive correlation between the levels of SLAI and CSF p-Tau. No correlation was found when SLAI was analysed together with t-Tau. These results demonstrate that mechanisms of cortical cholinergic activity are altered in patients bearing a pathological CSF hallmark of AD, suggesting that these peptides may have some influence on the cholinergic dysfunction in AD. We suggest that coupling of CSF biomarkers with neurophysiological parameters of central cholinergic function could be important to better detect ongoing mechanisms of neural degeneration in vivo.

Original languageEnglish
Pages (from-to)771-778
Number of pages8
JournalJournal of Neural Transmission
Volume119
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Cholinergic Agents
Cerebrospinal Fluid
Alzheimer Disease
tau Proteins
Cholinergic Neurons
Spinal Puncture
Amyloid beta-Peptides
Staphylococcal Protein A
Acetylcholine
Animal Models
Biomarkers
Inhibition (Psychology)
Peptides

Keywords

  • Aβ42
  • Alzheimer's disease
  • Cerebrospinal fluid
  • SLAI
  • TMS

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients. / Martorana, Alessandro; Esposito, Zaira; Di Lorenzo, Francesco; Giacobbe, Viola; Sancesario, Giulia Maria; Bucchi, Giulia; Bonnì, Sonia; Bernardini, Sergio; Sorge, Roberto; Sancesario, Giuseppe; Bernardi, Giorgio; Caltagirone, Carlo; Koch, Giacomo.

In: Journal of Neural Transmission, Vol. 119, No. 7, 07.2012, p. 771-778.

Research output: Contribution to journalArticle

Martorana, A, Esposito, Z, Di Lorenzo, F, Giacobbe, V, Sancesario, GM, Bucchi, G, Bonnì, S, Bernardini, S, Sorge, R, Sancesario, G, Bernardi, G, Caltagirone, C & Koch, G 2012, 'Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients', Journal of Neural Transmission, vol. 119, no. 7, pp. 771-778. https://doi.org/10.1007/s00702-012-0780-4
Martorana, Alessandro ; Esposito, Zaira ; Di Lorenzo, Francesco ; Giacobbe, Viola ; Sancesario, Giulia Maria ; Bucchi, Giulia ; Bonnì, Sonia ; Bernardini, Sergio ; Sorge, Roberto ; Sancesario, Giuseppe ; Bernardi, Giorgio ; Caltagirone, Carlo ; Koch, Giacomo. / Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients. In: Journal of Neural Transmission. 2012 ; Vol. 119, No. 7. pp. 771-778.
@article{52ce295d0ace42b78f6bc1fd3522ff07,
title = "Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients",
abstract = "The dysfunction of cholinergic neurons is a typical hallmark in Alzheimer's disease (AD). In animal models of AD, fragments of amyloid beta protein (Aβ) and Tau protein are thought to interfere with central cholinergic transmission, specifically with synthesis and release of acetylcholine. Thus, we aimed to investigate whether the cerebrospinal fluid (CSF) levels of Aβ42 and Tau proteins in AD patients could influence physiological central cholinergic activity. In AD patients (n = 19), central cholinergic function was evaluated in vivo by using short afferent latency inhibition (SLAI), and compared to age-matched healthy controls. In the same AD patients, CSF samples were collected through lumbar puncture to obtain individual levels of Aβ42, total Tau (t-Tau) and phosphorylated Tau (p-Tau) (Thr181). SLAI was decreased in AD patients in comparison to age-matched healthy controls. We found that in patients there was a negative correlation between the individual amount of cholinergic activity assessed by SLAI and the CSF levels of Aβ42. On the other hand, there was a positive correlation between the levels of SLAI and CSF p-Tau. No correlation was found when SLAI was analysed together with t-Tau. These results demonstrate that mechanisms of cortical cholinergic activity are altered in patients bearing a pathological CSF hallmark of AD, suggesting that these peptides may have some influence on the cholinergic dysfunction in AD. We suggest that coupling of CSF biomarkers with neurophysiological parameters of central cholinergic function could be important to better detect ongoing mechanisms of neural degeneration in vivo.",
keywords = "Aβ42, Alzheimer's disease, Cerebrospinal fluid, SLAI, TMS",
author = "Alessandro Martorana and Zaira Esposito and {Di Lorenzo}, Francesco and Viola Giacobbe and Sancesario, {Giulia Maria} and Giulia Bucchi and Sonia Bonn{\`i} and Sergio Bernardini and Roberto Sorge and Giuseppe Sancesario and Giorgio Bernardi and Carlo Caltagirone and Giacomo Koch",
year = "2012",
month = "7",
doi = "10.1007/s00702-012-0780-4",
language = "English",
volume = "119",
pages = "771--778",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer-Verlag Wien",
number = "7",

}

TY - JOUR

T1 - Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients

AU - Martorana, Alessandro

AU - Esposito, Zaira

AU - Di Lorenzo, Francesco

AU - Giacobbe, Viola

AU - Sancesario, Giulia Maria

AU - Bucchi, Giulia

AU - Bonnì, Sonia

AU - Bernardini, Sergio

AU - Sorge, Roberto

AU - Sancesario, Giuseppe

AU - Bernardi, Giorgio

AU - Caltagirone, Carlo

AU - Koch, Giacomo

PY - 2012/7

Y1 - 2012/7

N2 - The dysfunction of cholinergic neurons is a typical hallmark in Alzheimer's disease (AD). In animal models of AD, fragments of amyloid beta protein (Aβ) and Tau protein are thought to interfere with central cholinergic transmission, specifically with synthesis and release of acetylcholine. Thus, we aimed to investigate whether the cerebrospinal fluid (CSF) levels of Aβ42 and Tau proteins in AD patients could influence physiological central cholinergic activity. In AD patients (n = 19), central cholinergic function was evaluated in vivo by using short afferent latency inhibition (SLAI), and compared to age-matched healthy controls. In the same AD patients, CSF samples were collected through lumbar puncture to obtain individual levels of Aβ42, total Tau (t-Tau) and phosphorylated Tau (p-Tau) (Thr181). SLAI was decreased in AD patients in comparison to age-matched healthy controls. We found that in patients there was a negative correlation between the individual amount of cholinergic activity assessed by SLAI and the CSF levels of Aβ42. On the other hand, there was a positive correlation between the levels of SLAI and CSF p-Tau. No correlation was found when SLAI was analysed together with t-Tau. These results demonstrate that mechanisms of cortical cholinergic activity are altered in patients bearing a pathological CSF hallmark of AD, suggesting that these peptides may have some influence on the cholinergic dysfunction in AD. We suggest that coupling of CSF biomarkers with neurophysiological parameters of central cholinergic function could be important to better detect ongoing mechanisms of neural degeneration in vivo.

AB - The dysfunction of cholinergic neurons is a typical hallmark in Alzheimer's disease (AD). In animal models of AD, fragments of amyloid beta protein (Aβ) and Tau protein are thought to interfere with central cholinergic transmission, specifically with synthesis and release of acetylcholine. Thus, we aimed to investigate whether the cerebrospinal fluid (CSF) levels of Aβ42 and Tau proteins in AD patients could influence physiological central cholinergic activity. In AD patients (n = 19), central cholinergic function was evaluated in vivo by using short afferent latency inhibition (SLAI), and compared to age-matched healthy controls. In the same AD patients, CSF samples were collected through lumbar puncture to obtain individual levels of Aβ42, total Tau (t-Tau) and phosphorylated Tau (p-Tau) (Thr181). SLAI was decreased in AD patients in comparison to age-matched healthy controls. We found that in patients there was a negative correlation between the individual amount of cholinergic activity assessed by SLAI and the CSF levels of Aβ42. On the other hand, there was a positive correlation between the levels of SLAI and CSF p-Tau. No correlation was found when SLAI was analysed together with t-Tau. These results demonstrate that mechanisms of cortical cholinergic activity are altered in patients bearing a pathological CSF hallmark of AD, suggesting that these peptides may have some influence on the cholinergic dysfunction in AD. We suggest that coupling of CSF biomarkers with neurophysiological parameters of central cholinergic function could be important to better detect ongoing mechanisms of neural degeneration in vivo.

KW - Aβ42

KW - Alzheimer's disease

KW - Cerebrospinal fluid

KW - SLAI

KW - TMS

UR - http://www.scopus.com/inward/record.url?scp=84863430000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863430000&partnerID=8YFLogxK

U2 - 10.1007/s00702-012-0780-4

DO - 10.1007/s00702-012-0780-4

M3 - Article

VL - 119

SP - 771

EP - 778

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 7

ER -